BranchLab Raises $26M Series A Led by McKesson Ventures to Bring AI to Pharma Commercialization

BranchLab, a Boulder-based artificial intelligence platform focused on revolutionizing pharmaceutical commercialization, has successfully secured $26 million in Series A financing. The funding round, which brings the company’s total funding to $35 million, was led by McKesson Ventures, with notable participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The announcement was made on May 13, 2026, highlighting the growing interest in innovative solutions within the healthcare sector.

BranchLab aims to address the inefficiencies in pharmaceutical commercialization, an area that has historically relied on fragmented workflows and delayed analytics. By providing a unified, privacy-first AI platform, BranchLab enhances the efficacy of marketing strategies, achieving an average increase of nearly 70% in commercialization effectiveness across various therapeutic areas. The platform enables pharmaceutical companies to streamline patient identification, audience segmentation, and real-world measurement, thereby allowing teams to act swiftly on high-intent patient and healthcare professional audiences.

The strategic rationale behind this funding is underscored by the need for the pharmaceutical industry to modernize its approach to commercialization. As noted by Josh Walsh, CEO of BranchLab, the challenge has been to use rich data quickly and responsibly. The company’s innovative architecture allows for the training of models on health data within customer-controlled environments, deploying only non-sensitive demographic signals. This capability not only accelerates the commercialization process but also enhances the ability of pharmaceutical teams to engage with their target audiences effectively.

The investment from leading venture firms reflects a broader trend in the healthcare sector towards integrating advanced AI systems that prioritize privacy and operational efficiency. As Andrew Bouldin, Managing Partner at FCA Venture Partners, pointed out, the shift towards real-time data utilization within regulated environments is a significant advancement in pharmaceutical commercialization. Similarly, Cris De Luca from Sanofi Ventures highlighted the potential for BranchLab to become a core commercial intelligence layer, facilitating better connections between therapies and patients in an increasingly digital landscape.

Looking ahead, the implications of this funding extend beyond BranchLab itself, signaling a transformative moment for the pharmaceutical industry. As companies increasingly adopt AI-driven solutions, the emphasis on privacy-aware systems will likely reshape how therapies are marketed and accessed. With the new capital, BranchLab is poised to expand its enterprise deployments and deepen integrations across the healthcare ecosystem, reinforcing its role as a critical infrastructure provider in the evolving landscape of pharmaceutical commercialization.